Abcam, ab234631, Anti-C3b / iC3b antibody [1H8] - BSA and Azide free

Size: 100µg
Mouse Monoclonal C3 antibody. Carrier free. Suitable for WB, ELISA and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:1H8,
Isotype:IgG2,
Light chain type:kappa,
Carrier free:Yes,
Reacts with:Human,
Applications:ELISA, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab234631 is the carrier-free version of
ab231080
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein G, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
C3b protein also known as complement component 3b plays a significant role in the immune system aiding in the clearance of pathogens. It is a large glycoprotein with a mass of approximately 180 kDa. C3b is expressed mainly in the liver and released into the bloodstream as part of the complement system. Upon activation from its precursor C3 it becomes involved in opsonization enhancing the phagocytosis of pathogens by marking them for destruction by immune cells.
Biological function summary
C3b acts as a critical mediator in the immune system by forming complexes with other complement proteins. It is part of the alternative and classical pathways of the complement system. C3b can also convert itself into iC3b after cleavage by factor I and iC3b continues to facilitate phagocytosis but with reduced ability to promote further complement activation. This conversion ensures homeostasis and regulation preventing overactivation of the immune system.
Pathways
C3b participates in both the classical and alternative pathways of the complement system. It associates with proteins such as factor B and factor D to form the C3bBb complex in the alternative pathway acting as a C3 convertase that amplifies response. In the classical pathway C3b enhances the activity of C5 convertase facilitating the formation of the membrane attack complex. These pathways are vital in maintaining immune surveillance and response to infections.
Dysfunction or dysregulation of C3b activity links to autoimmune diseases and infectious diseases. For example atypical hemolytic uremic syndrome (aHUS) involves uncontrolled complement activation due to mutations affecting proteins like C3b. In such conditions C3b and related proteins such as factor H become therapeutic targets to modulate the complement system's overactivation. Studying the role of C3b in these diseases provides insight into potential interventions and novel treatments to manage complement-related pathologies.